Recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch pathway.
RhCol17 shows potential in protecting against blue light-induced skin aging in preclinical models, but human studies are needed to confirm its efficacy.
Where it sits
this study against the rest of the p21 (p021) corpusSummary and findings
The study investigated the effects of recombinant human collagen XVII (rhCol17) on blue light-induced photoaging in epidermal stem cells (ESCs) and Sprague-Dawley rats. RhCol17 improved ESC viability, reduced senescence, and modulated inflammatory markers. In rats, rhCol17 alleviated skin dryness and reduced epidermal thickness without affecting organ histology.
Abstract
<h4>Background</h4>Epidermal stem cell (ESC) degeneration is closely associated with skin aging and functional deterioration. Type XVII collagen (COL17A1) critically regulates ESC polarity and epidermal homeostasis. This study investigated the protective effects of recombinant human COLXVII (rhCol17) against blue light-induced photoaging, particularly on ESC.<h4>Methods</h4>Blue light-induced photoaging models were established using <i>in vitro</i> ESCs and <i>in vivo</i> Sprague-Dawley rats. Transcriptomic profiling was conducted to systematically elucidate the underlying mechanisms.<h4>Results</h4>In photoaging ESCs, rhCol17 enhanced ESC viability and migratory capacity, decreased senescence cells, while suppressing ROS production and the secretion of pro-inflammatory factors interleukin (IL)-6, IL-1β and tumor necrosis factor-α. Furthermore, rhCol17 upregulated stem cell markers COL17A1, ITGB1, ITGA6 and P63. In photoaging rat models, rhCol17 alleviated skin dryness, reduced epidermal thickness, delayed aging, and increased the levels of COL17A1 and ITGB1. Importantly, rhCol17 treatment does not affect organ histology or biochemical parameters in rats. Mechanistically, rhCol17 could inhibit the levels of Notch1 and HES1, and senescence markers P16, P21, and P53 in photoaging ESCs and rat skin. Additionally, the ADAM10 inhibitor GI254023X slightly reduced or did not significantly alter the proportion of senescent cells or the expression levels of P16, P21, and P53 in rhCol17-treated BL-induced ESCs, whereas the Notch activator VPA significantly reversed these protective effects of rhCol17.<h4>Conclusion</h4>This study demonstrates that rhCol17 counteracts blue light-induced ESC dysfunction and epidermal photoaging, suggesting therapeutic potential for photoaging intervention.
Background
The study addresses the issue of epidermal stem cell (ESC) degeneration, which is linked to skin aging and deterioration. Type XVII collagen (COL17A1) is known to regulate ESC polarity and epidermal homeostasis. This research is significant as it explores the protective effects of recombinant human COLXVII against blue light-induced photoaging, a growing concern due to increased exposure to artificial lighting.
Methods
The study utilized both in vitro and in vivo models to investigate the effects of rhCol17. Blue light-induced photoaging models were established using epidermal stem cells and Sprague-Dawley rats. Transcriptomic profiling was employed to understand the mechanisms involved. The primary outcomes included ESC viability, senescence, ROS production, and inflammatory marker secretion.
Results
RhCol17 treatment enhanced ESC viability and migratory capacity, decreased senescence cells, and suppressed ROS production. It also reduced the secretion of pro-inflammatory factors IL-6, IL-1β, and TNF-α. In rats, rhCol17 alleviated skin dryness, reduced epidermal thickness, and increased the levels of COL17A1 and ITGB1. The treatment did not affect organ histology or biochemical parameters in rats. Mechanistically, rhCol17 inhibited Notch1 and HES1 levels, as well as senescence markers P16, P21, and P53.
Interpretation
The findings suggest that rhCol17 may offer protective effects against blue light-induced photoaging by modulating key pathways and markers associated with skin aging. However, the clinical significance of these effects remains uncertain due to the reliance on animal and in vitro models. The study's results align with existing literature on the role of COL17A1 in skin homeostasis, but further research is needed to confirm these effects in humans.
Key findings
- RhCol17 enhanced ESC viability and migratory capacity.
- RhCol17 decreased senescence cells and suppressed ROS production.
- RhCol17 reduced secretion of IL-6, IL-1β, and TNF-α.
- RhCol17 alleviated skin dryness and reduced epidermal thickness in rats.
- RhCol17 inhibited Notch1 and HES1 levels in photoaging models.
Limitations
- in vitro and animal models only
- lack of detailed quantitative data
- no human data
- potential species differences
- mechanistic focus without clinical endpoints